170 related articles for article (PubMed ID: 37491057)
21. Papillary Craniopharyngioma: A Type of Tumor Primarily Impairing the Hypothalamus - A Comprehensive Anatomo-Clinical Characterization of 350 Well-Described Cases.
Prieto R; Barrios L; Pascual JM
Neuroendocrinology; 2022; 112(10):941-965. PubMed ID: 35108706
[TBL] [Abstract][Full Text] [Related]
22. Craniopharyngiomas.
Hamblin R; Tsermoulas G; Karavitaki N
Presse Med; 2021 Dec; 50(4):104078. PubMed ID: 34688870
[TBL] [Abstract][Full Text] [Related]
23. Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas.
Rickert CH; Paulus W
J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):260-1. PubMed ID: 12531965
[TBL] [Abstract][Full Text] [Related]
24. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
25. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
26. Beta-catenin mutations in craniopharyngiomas and pituitary adenomas.
Oikonomou E; Barreto DC; Soares B; De Marco L; Buchfelder M; Adams EF
J Neurooncol; 2005 Jul; 73(3):205-9. PubMed ID: 15980970
[TBL] [Abstract][Full Text] [Related]
27. Integrating Systemic Therapies into the Multimodality Therapy of Patients with Craniopharyngioma.
Gritsch D; Santagata S; Brastianos PK
Curr Treat Options Oncol; 2024 Feb; 25(2):261-273. PubMed ID: 38300480
[TBL] [Abstract][Full Text] [Related]
28. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
29. Monitoring the expression profiles of integrins and adhesion/growth-regulatory galectins in adamantinomatous craniopharyngiomas: their ability to regulate tumor adhesiveness to surrounding tissue and their contribution to prognosis.
Lefranc F; Mijatovic T; Decaestecker C; Kaltner H; André S; Brotchi J; Salmon I; Gabius HJ; Kiss R
Neurosurgery; 2005 Apr; 56(4):763-76. PubMed ID: 15792515
[TBL] [Abstract][Full Text] [Related]
30. Papillary craniopharyngioma: a clinicopathological study of 48 cases.
Crotty TB; Scheithauer BW; Young WF; Davis DH; Shaw EG; Miller GM; Burger PC
J Neurosurg; 1995 Aug; 83(2):206-14. PubMed ID: 7616262
[TBL] [Abstract][Full Text] [Related]
31. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
[No Abstract] [Full Text] [Related]
32. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
[TBL] [Abstract][Full Text] [Related]
33. Craniopharyngioma.
Müller HL; Merchant TE; Warmuth-Metz M; Martinez-Barbera JP; Puget S
Nat Rev Dis Primers; 2019 Nov; 5(1):75. PubMed ID: 31699993
[TBL] [Abstract][Full Text] [Related]
34. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
[TBL] [Abstract][Full Text] [Related]
35. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
[TBL] [Abstract][Full Text] [Related]
36. Craniopharyngioma: a pathologic, clinical, and surgical review.
Fernandez-Miranda JC; Gardner PA; Snyderman CH; Devaney KO; Strojan P; Suárez C; Genden EM; Rinaldo A; Ferlito A
Head Neck; 2012 Jul; 34(7):1036-44. PubMed ID: 21584897
[TBL] [Abstract][Full Text] [Related]
37. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
Erfurth EM
J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
[TBL] [Abstract][Full Text] [Related]
38. Association of pituitary stalk management with endocrine outcomes and recurrence in microsurgery of craniopharyngiomas: A meta-analysis.
Li K; Lu X; Yang N; Zheng J; Huang B; Li L
Clin Neurol Neurosurg; 2015 Sep; 136():20-4. PubMed ID: 26056807
[TBL] [Abstract][Full Text] [Related]
39. Pediatric craniopharyngiomas: clinicomorphological study of 189 cases.
Zhang YQ; Wang CC; Ma ZY
Pediatr Neurosurg; 2002 Feb; 36(2):80-4. PubMed ID: 11893889
[TBL] [Abstract][Full Text] [Related]
40. Growth patterns of craniopharyngiomas: clinical analysis of 226 patients.
Pan J; Qi S; Liu Y; Lu Y; Peng J; Zhang X; Xu Y; Huang GL; Fan J
J Neurosurg Pediatr; 2016 Apr; 17(4):418-33. PubMed ID: 26636252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
